September 17, 2019 10:29 AM EDT

Amgen inks discovery deal with Hummingbird; Merck gains priority review for Ebola vaccine

ENDPOINTS

→ Amgen has enlisted Hummingbird Bioscience on a new antibody discovery pact, turning over some novel targets to see if the smaller player’s systems …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amgen inks discovery deal with Hummingbird; Merck gains priority review for Ebola vaccine

ENDPOINTS

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Am­gen inks dis­cov­ery deal with Hum­ming­bird; Mer­ck gains pri­or­i­ty re­view for Ebo­la vac­cine

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Amgen inks discovery deal with Hummingbird; Merck gains priority review for Ebola vaccine